SU1648248A3 - Способ разделени смеси @ - и @ -энантиомеров 4-[1-(2,3-диметилфенил)этил]-1Н-имидазола - Google Patents

Способ разделени смеси @ - и @ -энантиомеров 4-[1-(2,3-диметилфенил)этил]-1Н-имидазола Download PDF

Info

Publication number
SU1648248A3
SU1648248A3 SU884356076A SU4356076A SU1648248A3 SU 1648248 A3 SU1648248 A3 SU 1648248A3 SU 884356076 A SU884356076 A SU 884356076A SU 4356076 A SU4356076 A SU 4356076A SU 1648248 A3 SU1648248 A3 SU 1648248A3
Authority
SU
USSR - Soviet Union
Prior art keywords
enantiomers
receptors
mixture
enantiomer
separation
Prior art date
Application number
SU884356076A
Other languages
English (en)
Russian (ru)
Inventor
Йоханнес Карьялайнен Арто
Эйнари Виртанен Раимо
Юхани Саволайнен Эйно
Original Assignee
Фармос-Ихтюмя Ой (Фирма)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10620775&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SU1648248(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Фармос-Ихтюмя Ой (Фирма) filed Critical Фармос-Ихтюмя Ой (Фирма)
Application granted granted Critical
Publication of SU1648248A3 publication Critical patent/SU1648248A3/ru
Priority to LV930435A priority Critical patent/LV5241A3/xx
Priority to LTRP761A priority patent/LT2214B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/58—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Optical Fibers, Optical Fiber Cores, And Optical Fiber Bundles (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Optical Record Carriers And Manufacture Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SU884356076A 1987-07-16 1988-06-28 Способ разделени смеси @ - и @ -энантиомеров 4-[1-(2,3-диметилфенил)этил]-1Н-имидазола SU1648248A3 (ru)

Priority Applications (2)

Application Number Priority Date Filing Date Title
LV930435A LV5241A3 (lv) 1987-07-16 1993-05-28 enantiomeru maisijuma sadalisanas metode 4-Ú1-(2,3-dimetilfenil)etil¾-1h-imidazola d- un l-
LTRP761A LT2214B (lt) 1987-07-16 1993-07-07 4-(1-(2,3-dimetilfenil) etil) -h-imadazolo d-ir 1-enantiomeru misinio atskyrimo budas

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB8716803A GB2206880B (en) 1987-07-16 1987-07-16 Optical isomers of an imidazole derivative

Publications (1)

Publication Number Publication Date
SU1648248A3 true SU1648248A3 (ru) 1991-05-07

Family

ID=10620775

Family Applications (1)

Application Number Title Priority Date Filing Date
SU884356076A SU1648248A3 (ru) 1987-07-16 1988-06-28 Способ разделени смеси @ - и @ -энантиомеров 4-[1-(2,3-диметилфенил)этил]-1Н-имидазола

Country Status (29)

Country Link
US (1) US4910214A (https=)
EP (1) EP0300652B1 (https=)
JP (1) JPH0625138B2 (https=)
KR (1) KR940007311B1 (https=)
CN (1) CN1022323C (https=)
AT (1) ATE71941T1 (https=)
AU (1) AU600839B2 (https=)
BG (1) BG60473B2 (https=)
CA (1) CA1337659C (https=)
CY (2) CY1787A (https=)
DD (1) DD281807A5 (https=)
DE (2) DE3867945D1 (https=)
DK (1) DK165788C (https=)
ES (1) ES2038757T3 (https=)
FI (1) FI95375C (https=)
GB (1) GB2206880B (https=)
GR (1) GR3003878T3 (https=)
HK (1) HK56094A (https=)
HU (1) HU198693B (https=)
IE (1) IE60456B1 (https=)
IL (1) IL87076A0 (https=)
LU (1) LU91010I2 (https=)
NL (1) NL300117I2 (https=)
NO (2) NO170579C (https=)
NZ (1) NZ225362A (https=)
PT (1) PT88013B (https=)
SU (1) SU1648248A3 (https=)
UA (1) UA5560A1 (https=)
ZA (1) ZA885134B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2743999C2 (ru) * 2016-07-22 2021-03-01 Юниверсите Де Руан Способ разделения солей баклофена

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2215206B (en) * 1988-02-29 1991-07-03 Farmos Oy 4-substituted imidazole derivatives useful in perioperative care
US5124157A (en) * 1989-08-18 1992-06-23 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
US5120713A (en) * 1990-09-10 1992-06-09 Applied Research Systems Ars Holding N.V. Treatment of obesity with an alpha-2-adrenergic agonist and a growth hormone releasing peptide
GB9111732D0 (en) * 1991-05-31 1991-07-24 Orion Yhtymae Oy The use of certain salts of medetomidine and its optically active enantiomers to regulate the rate of transdermal administration of the drugs
GB2281206A (en) * 1993-08-25 1995-03-01 Orion Yhtymae Oy Use of dexmedetomidine
GB9425211D0 (en) * 1994-12-14 1995-02-15 Ucb Sa Substituted 1H-imidazoles
IN187238B (https=) * 1995-06-30 2002-03-09 Astra Ab
GB9521680D0 (en) * 1995-10-23 1996-01-03 Orion Yhtymo Oy New use of imidazole derivatives
US5866579A (en) 1997-04-11 1999-02-02 Synaptic Pharmaceutical Corporation Imidazole and imidazoline derivatives and uses thereof
US6716867B1 (en) 1998-04-01 2004-04-06 Orion Corporation Use of dexmedetomidine for ICU sedation
AR015744A1 (es) * 1998-04-01 2001-05-16 Orion Corp Uso de dexmedetomidina para sedacion en terapia intensiva
DE60024855T2 (de) 1999-10-29 2006-08-31 Orion Corp. Verwendung eines imidazolderivats zur behandlung oder verhütung von hypotension und schock
US6388090B2 (en) * 2000-01-14 2002-05-14 Orion Corporation Imidazole derivatives
US7141597B2 (en) * 2003-09-12 2006-11-28 Allergan, Inc. Nonsedating α-2 agonists
WO2007056457A2 (en) 2005-11-09 2007-05-18 Combinatorx, Incorporated Methods, compositions, and kits for the treatment of medical conditions
CN102488652B (zh) 2006-03-16 2014-06-18 特瑞斯制药股份有限公司 含有药物-离子交换树脂复合物的经修饰释放的制剂
US7795263B2 (en) * 2008-07-08 2010-09-14 Wildlife Laboratories, Inc. Pharmaceutical combination for and method of anesthetizing and immobilizing non-domesticated mammals
US20100196286A1 (en) * 2008-12-01 2010-08-05 Armer Thomas A Inhalation delivery methods and devices
WO2010074753A1 (en) 2008-12-23 2010-07-01 Map Pharmaceuticals, Inc. Inhalation devices and related methods for administration of sedative hypnotic compounds
RU2572692C2 (ru) * 2009-05-15 2016-01-20 Рекро Фарма, Инк. Сублингвальные композиции дексмедетомидина и способы их применения
CN101671305A (zh) * 2009-09-29 2010-03-17 北京华禧联合科技发展有限公司 一种拆分美托咪定的左旋及右旋对映体的方法
CN102464619A (zh) * 2010-11-17 2012-05-23 桑迪亚医药技术（上海）有限责任公司 一种左旋4-[1-(2,3-二甲基苯基)乙基]-1r-咪唑消旋化方法
US20130096170A1 (en) 2011-10-14 2013-04-18 Hospira, Inc. Methods of treating pediatric patients using dexmedetomidine
WO2013069025A1 (en) 2011-11-11 2013-05-16 Neon Laboratories Ltd. "process for the preparation of dexmedetomidine"
AU2012352528B9 (en) 2011-12-11 2017-11-02 Baudax Bio, Inc. Intranasal dexmedetomidine compositions and methods of use thereof
US8242158B1 (en) 2012-01-04 2012-08-14 Hospira, Inc. Dexmedetomidine premix formulation
ITMI20120311A1 (it) * 2012-02-29 2013-08-30 Edmond Pharma Srl Procedimento per la risoluzione di medetomidina e recupero dell'enantiomero indesiderato
CA2880456A1 (en) 2012-08-15 2014-02-20 Tris Pharma, Inc. Methylphenidate extended release chewable tablet
DK2906213T3 (en) * 2012-10-15 2018-02-19 Orion Corp VETERINARY PROCEDURE FOR RELIEFING NOISE SENSITIVITY
CA2924233C (en) 2013-10-07 2018-10-23 Teikoku Pharma Usa, Inc. Methods and compositions for treating attention deficit hyperactivity disorder, anxiety and insomnia using dexmedetomidine transdermal compositions
BR112016006848A2 (pt) 2013-10-07 2017-08-01 Teikoku Pharma Usa Inc métodos e composições para distribuição transdérmica de uma quantidade não sedativa de dexmedetomidina
KR101827980B1 (ko) 2013-10-07 2018-02-13 테이코쿠 팔마 유에스에이, 인코포레이티드 덱스메데토미딘 경피 전달 장치 및 이의 사용 방법
CN105175339B (zh) * 2015-10-09 2018-01-16 辰欣药业股份有限公司 一种制备盐酸右美托咪定的方法
US9717796B1 (en) 2016-04-20 2017-08-01 Slypharma, Llc Heat sterilizeable, premixed, ready to use dexmedetomidine solution packaged in a flexible plastic container
TWI764951B (zh) 2016-10-31 2022-05-21 美商帝國製藥美國股份有限公司 用於處理疼痛之右美托咪啶經皮遞送裝置
US11160791B2 (en) 2018-11-01 2021-11-02 Medefil, Inc. Dexmedetomidine injection premix formulation in ready to use (RTU) bags
CN115197149B (zh) * 2021-04-02 2023-09-22 四川大学华西医院 一种5-苄基咪唑类化合物及其制备方法和用途
CN114671811A (zh) * 2022-04-14 2022-06-28 南京正科医药股份有限公司 一种右美托咪定拆分副产物的外消旋化回收方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU518569B2 (en) * 1979-08-07 1981-10-08 Farmos-Yhtyma Oy 4-benzyl- and 4-benzoyl imidazole derivatives
GB2092569B (en) * 1981-02-05 1984-09-19 Farmos Oy Substituted imidazole derivatives and their preparation and use
GB2101114B (en) * 1981-07-10 1985-05-22 Farmos Group Ltd Substituted imidazole derivatives and their preparation and use
FI844786A0 (fi) 1984-12-04 1984-12-04 Farmos Oy Terapeutiskt utnyttjbar foerening.
DE3531682A1 (de) * 1985-09-05 1987-03-12 Thomae Gmbh Dr K (+)-6-chlor-5,10-dihydro-5-((1-methyl-4- piperidinyl)acetyl)-11h-dibenzo(b,e)(1,4) diazepin-11-on, seine isolierung und verwendung als arzneimittel

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Грингатейн Дж. Хими аминокислот и пептидов. - Мир, 1965, с.64-66. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2743999C2 (ru) * 2016-07-22 2021-03-01 Юниверсите Де Руан Способ разделения солей баклофена

Also Published As

Publication number Publication date
NO883155D0 (no) 1988-07-15
DE10399005I2 (de) 2012-06-06
GR3003878T3 (https=) 1993-03-16
IE60456B1 (en) 1994-07-13
KR940007311B1 (ko) 1994-08-12
NO883155L (no) 1989-01-17
PT88013A (pt) 1989-06-30
IE882174L (en) 1989-01-16
GB2206880A (en) 1989-01-18
LU91010I2 (fr) 2003-06-19
KR890002030A (ko) 1989-04-07
BG60473B2 (bg) 1995-04-28
UA5560A1 (uk) 1994-12-28
CN1022323C (zh) 1993-10-06
PT88013B (pt) 1995-03-01
CA1337659C (en) 1995-11-28
US4910214A (en) 1990-03-20
ATE71941T1 (de) 1992-02-15
DK386288D0 (da) 1988-07-11
HK56094A (en) 1994-06-03
DE3867945D1 (de) 1992-03-05
HU198693B (en) 1989-11-28
ES2038757T3 (es) 1993-08-01
GB8716803D0 (en) 1987-08-19
NL300117I1 (nl) 2003-05-01
JPH0625138B2 (ja) 1994-04-06
IL87076A0 (en) 1988-12-30
CN1030576A (zh) 1989-01-25
NO170579B (no) 1992-07-27
EP0300652B1 (en) 1992-01-22
NO2003004I2 (no) 2005-03-21
FI95375B (fi) 1995-10-13
CY2004006I2 (el) 2009-11-04
DK165788C (da) 1993-06-14
GB2206880B (en) 1991-04-24
FI882819L (fi) 1989-01-17
FI882819A0 (fi) 1988-06-14
HUT48218A (en) 1989-05-29
DD281807A5 (de) 1990-08-22
CY1787A (en) 1995-10-20
DK386288A (da) 1989-01-17
AU1894188A (en) 1989-01-19
AU600839B2 (en) 1990-08-23
NO170579C (no) 1992-11-04
FI95375C (fi) 1996-01-25
NZ225362A (en) 1990-07-26
DK165788B (da) 1993-01-18
NL300117I2 (nl) 2003-10-01
ZA885134B (en) 1989-04-26
JPS6434968A (en) 1989-02-06
CY2004006I1 (el) 2009-11-04
EP0300652A1 (en) 1989-01-25
DE10399005I1 (de) 2003-06-05

Similar Documents

Publication Publication Date Title
SU1648248A3 (ru) Способ разделени смеси @ - и @ -энантиомеров 4-[1-(2,3-диметилфенил)этил]-1Н-имидазола
DE69032725T2 (de) ZNS-wirksame 8-Heterocyclyl-2-aminotetralin Derivate
Doxey et al. Selectivity of blocking agents for pre-and postsynaptic alpha-adrenoceptors
US20080132576A1 (en) Methods and compositions for modulating alpha adrenergic receptor activity
SU1598869A3 (ru) Способ получени транс-3,4-изомеров производных 4-(3-оксифенил)-пиперидина
CH616668A5 (https=)
FI67543C (fi) Foerfarande foer framstaellning av farmakologiskt aktiv 2-(2-(1,4-benzodioxanyl))-2-imidazolin
SK49598A3 (en) (r)-(-)-methyl phenyl oxazolidinone derivatives, process for producing same, medicaments containing same and use thereof
BR112013006320B1 (pt) Composto, composição farmacêutica e seu uso
EP1280525A2 (en) Methods and compositions for modulating alpha adrenergic receptor activity
DE69520430T2 (de) Meta substituierte arylalkylamine und therapeutische und diagnostische verwendung davon
EP4304596A1 (en) Compositions and methods for treating polycythemia
WO2000037452A1 (de) Sulfonyloxazolamine als therapeutische wirkstoffe
CH544066A (de) Verfahren zur Herstellung von Fluorenverbindungen
DE2733698A1 (de) 1-niederalkyl-4,5-dihydro-5-phenyl- 2-niederalkoxycarbonylaminoimidazole und deren im phenylrest substituierte derivate
US4110463A (en) Imidazole-2-carbamates
MURAMATSU et al. DJ-7141, a new alpha-2 agonist with only a mild hypotensive action
US6083964A (en) Optical resolution of racemic aminoalkylpyridine anticonvulsants and (+) aminoalkylpyridine enantiomers as highly potent orally effective anticonvulsant drugs and excitatory amino acid antagonists
SU1299506A3 (ru) Способ получени фармацевтически приемлемых солей транс-4 @ -5 @ -пропил-4,4а,5,6,7,8,8а,9-октагидро- @ /и @ / пиразоло /3,4- @ / хинолина
EP0108766A1 (fr) Isomeres optiques de la (benzodioxanne-1,4 yl-2)-2delta-2 imidazoline, leur preparation et leur application en therapeutique
JPS60123418A (ja) 血管拡張剤
JPH06510060A (ja) スピロ環式ベンゾピランイミダゾリン類
JPH0453871B2 (https=)
JPS62242673A (ja) てんかんおよび不安状態の予防および治療用２，４，６−トリス−第三ブチルアミノ−１，３，５−トリアジン